Zika in Infants and Pregnancy (ZIP)

NCT ID: NCT02856984

Last Updated: 2021-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6461 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-30

Study Completion Date

2020-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of this multisite, multicountry Zika in Infants and Pregnancy (ZIP) study is to assess the strength of the association between Zika virus infection (ZIKV) during pregnancy and adverse maternal/fetal outcomes and the risk of vertical transmission. The study will prospectively enroll a cohort of pregnant women up to 17 weeks and 6 days gestation and subjects at any gestational age with acute Zika infection, confirmed by serology or PCR (polymerase chain reaction) test. The study will follow these women through their pregnancy to identify for clinical evidence of acute ZIKV, while controlling for potential confounders. Outcomes in the women, the developing fetus, and infants will be assessed. All protocol-specified data will be recorded and entered in a central data management system for the purposes of analysis of composite data from the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of this multisite, multicountry Zika in Infants and Pregnancy (ZIP) study is to assess the strength of the association between Zika virus infection (ZIKV) during pregnancy and adverse maternal/fetal outcomes and the risk of vertical transmission. The study will prospectively enroll a cohort of pregnant women up to 17 weeks and 6 days gestation and subjects at any gestational age with acute Zika infection, confirmed by serology or PCR (polymerase chain reaction) test. The study will follow these women through their pregnancy to identify for clinical evidence of acute ZIKV, while controlling for potential confounders. Outcomes in the women, the developing fetus, and infants will be assessed. All protocol-specified data will be recorded and entered in a central data management system for the purposes of analysis of composite data from the study.

The study will recruit up to10,000 pregnant women in their first trimester from ZIKV-endemic regions and follow them longitudinally to study the impact of incident ZIKV during pregnancy on maternal, fetal, and newborn outcomes. Researchers will identify cases of incident ZIKV among pregnant women by monitoring for symptoms of Zika-like illness and performing serial laboratory sampling for diagnosis of seroconversion and viral shedding. After delivery, infants born with evidence of ZIKV or born to mothers diagnosed with incident virus infection will be followed in a prospective longitudinal cohort for at least 1 year. In addition, a control group of infants born to mothers without evidence of ZIKV during pregnancy will be followed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zika Virus Disease (Disorder)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZIKV infected women

The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.

No interventions assigned to this group

Control (uninfected women)

The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent
* Age \>15 years
* Assent and consent as required per local country regulations
* Confirmation of pregnancy by beta human chorionic gonadotropin (hCG) measurement in blood/urine or ultrasound confirmation of pregnancy with fetal heart tones present
* Pregnant women up to 17 weeks and 6 days gestation and subjects at any gestational age with acute Zika infection, confirmed by serology or PCR (polymerase chain reaction) test.


* All infants born to women enrolled in the observational cohort are eligible for enrollment

Exclusion Criteria

* Women who cannot adhere to proposed testing schedule
* Pregnant women enrolled in other research including other ZIKV research


* Mother or custodial parent does not consent to have child participate
* Infants born to mothers that are not part of the ZIP cohort study
Minimum Eligible Age

15 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

National Institute of Environmental Health Sciences (NIEHS)

NIH

Sponsor Role collaborator

Oswaldo Cruz Foundation

OTHER

Sponsor Role collaborator

RTI International

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ricardo Ximenes, MD

Role: PRINCIPAL_INVESTIGATOR

Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE

William Britt, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama Birmingham School of Medicine

Marisa Mussi, MD

Role: PRINCIPAL_INVESTIGATOR

Ribeirão Preto Medical School, University of São Paulo

Albert Ko, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University, Laboratory of Epidemiology and Public Health

Deolinda Scalabrin

Role: PRINCIPAL_INVESTIGATOR

Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS

Marisa Elisabeth Lopes

Role: PRINCIPAL_INVESTIGATOR

Instituto Fernandes Figueira - FIOCRUZ

Ana Garces, MD

Role: PRINCIPAL_INVESTIGATOR

Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP)

Jose Cordero, MD

Role: PRINCIPAL_INVESTIGATOR

University of Georgia

Carmen Milagros Velez Vega, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Puerto Rico

George Seage, MD

Role: PRINCIPAL_INVESTIGATOR

Harvard University School of Public Health

Carmen Zorilla, MD

Role: PRINCIPAL_INVESTIGATOR

University of Puerto Rico

Eva Harris, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Californina Berkeley

Angel Balmaseda

Role: PRINCIPAL_INVESTIGATOR

MINSA Central

Juan F Arias, MD

Role: PRINCIPAL_INVESTIGATOR

St. Jude Children's Research Hospital

Jill Lebov, PhD

Role: PRINCIPAL_INVESTIGATOR

RTI International

Teresa Ochoa Woodell, PhD

Role: PRINCIPAL_INVESTIGATOR

Universidad Peruana Cayetano Heredia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS; Rue Waldemar Falcao

Salvador, Estado de Bahia, Brazil

Site Status

Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE

Recife, Pernambuco, Brazil

Site Status

Instituto Fernandes Figueira - FIOCRUZ

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - Monte Alegre

Ribeirão Preto, São Paulo, Brazil

Site Status

Centro Medico Imbanaco

Cali, , Colombia

Site Status

Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP)

Guatemala City, , Guatemala

Site Status

MINSA Central

Managua, , Nicaragua

Site Status

Universidad Peruana

Lima, , Peru

Site Status

University of Puerto Rico Medical Sciences Campus

San Juan, , Puerto Rico

Site Status

University of Puerto Rico - Recinto de Río Piedras

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil Colombia Guatemala Nicaragua Peru Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations; 1 February 2016. Available at http://www.who.int/ mediacentre/news/statements/2016/1st-emergency-committee-zika/en/

Reference Type BACKGROUND

Petersen EE, Staples JE, Meaney-Delman D, Fischer M, Ellington SR, Callaghan WM, Jamieson DJ. Interim Guidelines for Pregnant Women During a Zika Virus Outbreak--United States, 2016. MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):30-3. doi: 10.15585/mmwr.mm6502e1.

Reference Type BACKGROUND
PMID: 26796813 (View on PubMed)

Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Milliken S, Tiley C. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet. 1990 Dec 8;336(8728):1417-20. doi: 10.1016/0140-6736(90)93111-2.

Reference Type BACKGROUND
PMID: 1978880 (View on PubMed)

CDC. Chikungunya virus. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/chikungunya/hc/clinicalevaluation.html

Reference Type BACKGROUND

Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva: World Health Organization; 2009. Available from http://www.ncbi.nlm.nih.gov/books/NBK143157/

Reference Type BACKGROUND
PMID: 23762963 (View on PubMed)

CDC Zika Virus; Areas with Zika http://www.cdc.gov/zika/geo/index.html

Reference Type BACKGROUND

Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet Gynecol. 2016 Jan;47(1):6-7. doi: 10.1002/uog.15831. No abstract available.

Reference Type BACKGROUND
PMID: 26731034 (View on PubMed)

CDC. West Nile virus: insect repellent use & safety. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/westnile/faq/repellent.html.

Reference Type BACKGROUND

CDC. Zika virus. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/zika/index.html

Reference Type BACKGROUND

Oduyebo T, Petersen EE, Rasmussen SA, Mead PS, Meaney-Delman D, Renquist CM, Ellington SR, Fischer M, Staples JE, Powers AM, Villanueva J, Galang RR, Dieke A, Munoz JL, Honein MA, Jamieson DJ. Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure - United States, 2016. MMWR Morb Mortal Wkly Rep. 2016 Feb 12;65(5):122-7. doi: 10.15585/mmwr.mm6505e2.

Reference Type BACKGROUND
PMID: 26866840 (View on PubMed)

Babaliche P, Doshi D. Catching Dengue Early: Clinical Features and Laboratory Markers of Dengue Virus Infection. J Assoc Physicians India. 2015 May;63(5):38-41.

Reference Type BACKGROUND
PMID: 26591143 (View on PubMed)

Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011 Dec;3(12):2374-95. doi: 10.3390/v3122374. Epub 2011 Nov 25.

Reference Type BACKGROUND
PMID: 22355444 (View on PubMed)

Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. Am J Trop Med Hyg. 2012 Dec;87(6):1112-5. doi: 10.4269/ajtmh.2012.12-0182. Epub 2012 Oct 29.

Reference Type BACKGROUND
PMID: 23109371 (View on PubMed)

Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003 Mar;9(3):376-9. doi: 10.3201/eid0903.020531.

Reference Type BACKGROUND
PMID: 12643836 (View on PubMed)

http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Informes %20Arbovirales/Reporte%20ArboV%20semana%204-2016.pdf

Reference Type BACKGROUND

Chervenak FA, Jeanty P, Cantraine F, Chitkara U, Venus I, Berkowitz RL, Hobbins JC. The diagnosis of fetal microcephaly. Am J Obstet Gynecol. 1984 Jul 1;149(5):512-7. doi: 10.1016/0002-9378(84)90027-9.

Reference Type BACKGROUND
PMID: 6742021 (View on PubMed)

Chervenak FA, Rosenberg J, Brightman RC, Chitkara U, Jeanty P. A prospective study of the accuracy of ultrasound in predicting fetal microcephaly. Obstet Gynecol. 1987 Jun;69(6):908-10.

Reference Type BACKGROUND
PMID: 3554067 (View on PubMed)

Kurtz AB, Wapner RJ, Rubin CS, Cole-Beuglet C, Ross RD, Goldberg BB. Ultrasound criteria for in utero diagnosis of microcephaly. J Clin Ultrasound. 1980 Feb;8(1):11-6. doi: 10.1002/jcu.1870080104.

Reference Type BACKGROUND
PMID: 6766470 (View on PubMed)

Hutchon DJ. Fetal ultrasound biometry: 1. Head reference values. Br J Obstet Gynaecol. 1999 Aug;106(8):875-6. doi: 10.1111/j.1471-0528.1999.tb08417.x. No abstract available.

Reference Type BACKGROUND
PMID: 10453845 (View on PubMed)

Berger I. Prenatal microcephaly: can we be more accurate? J Child Neurol. 2009 Jan;24(1):97-100. doi: 10.1177/0883073808321045.

Reference Type BACKGROUND
PMID: 19168823 (View on PubMed)

Julie A Boom; Microcephaly in infants and children: Etiology and evaluation UpToDate http://www.uptodate.com/contents/microcephaly-in-infants-and-children- etiology-and-evaluation?source=machineLearning&search=microcephaly+in +pregnacy&selectedTitle=2~130§ionRank=3&anchor=H55603463#H55603463 Accessed on February 16, 2016

Reference Type BACKGROUND

Tolmie JL, McNay M, Stephenson JB, Doyle D, Connor JM. Microcephaly: genetic counselling and antenatal diagnosis after the birth of an affected child. Am J Med Genet. 1987 Jul;27(3):583-94. doi: 10.1002/ajmg.1320270311.

Reference Type BACKGROUND
PMID: 3307411 (View on PubMed)

Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EJ, Simpson AJ, Brooks TJ, Hewson R. Detection of Zika Virus in Semen. Emerg Infect Dis. 2016 May;22(5):940. doi: 10.3201/eid2205.160107. No abstract available.

Reference Type BACKGROUND
PMID: 27088817 (View on PubMed)

Medscape Medical News; FDA Issues Guidance to Protect Blood Supply From Zika Virus http://www.medscape.com/viewarticle/858976? nlid=100283_3901&src=wnl_newsalrt_160216_MSCPEDIT&uac=17333MK&impID=993653&faf=1

Reference Type BACKGROUND

Sarno M, Sacramento GA, Khouri R, do Rosario MS, Costa F, Archanjo G, Santos LA, Nery N Jr, Vasilakis N, Ko AI, de Almeida AR. Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl Trop Dis. 2016 Feb 25;10(2):e0004517. doi: 10.1371/journal.pntd.0004517. eCollection 2016 Feb.

Reference Type BACKGROUND
PMID: 26914330 (View on PubMed)

Brasil P, Pereira JP Jr, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, Rabello RS, Valderramos SG, Halai UA, Salles TS, Zin AA, Horovitz D, Daltro P, Boechat M, Raja Gabaglia C, Carvalho de Sequeira P, Pilotto JH, Medialdea-Carrera R, Cotrim da Cunha D, Abreu de Carvalho LM, Pone M, Machado Siqueira A, Calvet GA, Rodrigues Baiao AE, Neves ES, Nassar de Carvalho PR, Hasue RH, Marschik PB, Einspieler C, Janzen C, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med. 2016 Dec 15;375(24):2321-2334. doi: 10.1056/NEJMoa1602412. Epub 2016 Mar 4.

Reference Type BACKGROUND
PMID: 26943629 (View on PubMed)

Lebov JF, Nason M, Stolka KB, Ximenes R, Mussi-Pinhata MM, Moye J, Zorrilla CD, Velez Vega CM, Cordero JF, Scalabrin DMF, Ko AI, Moreira MEL, Galvao LA, Britt W, Marques ETA, Balmaseda A, Harris E, Arias JF, Schultz-Cherry S, Garces AL, Krebs NF, Ochoa TJ, Ugarte-Gil CA, Fogleman E, Gabriel E, Welton M, Irizarry CM, de Moura Negrini SB, Coutinho CM, de Barros Miranda-Filho D, Montarroyos UR, Cordeiro MT, Gajewski A, Osorio JE, Figueroa L. Zika in Infants and Pregnancy (ZIP) study: results from a prospective international cohort study of prenatal Zika virus infection and adverse fetal and infant outcomes. BMC Pregnancy Childbirth. 2025 Aug 30;25(1):903. doi: 10.1186/s12884-025-07774-y.

Reference Type DERIVED
PMID: 40885911 (View on PubMed)

Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galvao LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR 3rd, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth. 2019 Aug 7;19(1):282. doi: 10.1186/s12884-019-2430-4.

Reference Type DERIVED
PMID: 31391005 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GN ZIKA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transplacental Transmission of RSV (TTRSV)
NCT05443607 ACTIVE_NOT_RECRUITING
Maternal- Fetal Infection
NCT03371056 UNKNOWN NA